SCM
SAGE

Snow Capital Management’s Sage Therapeutics SAGE Stock Holding History

Snow Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$707K Buy
+12,450
New +$880K 0.1% 105

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Snow Capital Management's SAGE Position: Q2 2021 in Review

Snow Capital Management opened a new position in Sage Therapeutics (SAGE) in Q2 2021: 12,450 shares worth $707K. The stake represents 0.1% of the portfolio and ranks #105 among its holdings.

257 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Snow Capital Management held 12,450 shares of Sage Therapeutics worth $707K as of Q2 2021.
  • Sage Therapeutics was a new Snow Capital Management position in Q2 2021.
  • Sage Therapeutics made up 0.1% of Snow Capital Management's portfolio in Q2 2021, its #105 holding.
  • 257 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Snow Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.